Details for Patent: 12,090,148

Which drugs does patent 12,090,148 protect, and when does it expire?

Patent 12,090,148 protects QULIPTA and is included in one NDA.

This patent has twenty patent family members in eight countries.

Summary for Patent: 12,090,148

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
Inventor(s):	Joel Trugman, Michelle Finnegan
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US17/389,223
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,090,148
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,090,148

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,090,148					PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No	12,090,148					PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes	12,090,148					PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS

International Family Members for US Patent 12,090,148

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019283670
Australia	2021319090
Australia	2025202139
Brazil	112020025084
Brazil	112023001615
Canada	3102937